engleski

Enhanced antitumor activity of irinotecan combined with propolis and its polyphenolic compounds on Ehrlich ascites tumor in mice

Effects of anticancer drug irinotecan combined with ethanolic extract of propolis (EEP), water-soluble derivate of propolis (WSDP), quercetin, or naringin on the growth of Ehrlich ascites tumor (EAT) and life span of tumor bearing Swiss albino mice were studied. Test components were given to mice intraperitoneally (ip) at dose of 100 mg kg-1 for three consecutive days before the ip injection of EAT cells (1x106). Irinotecan was administered ip at dose of 50 mg kg-1 on days 1, 13, and 19 after tumor cell inoculation. The results clearly demonstrate the synergistic action of irinotecan and EEP on survival time. These results suggest the benefits of potential clinical trials using propolis preparation EEP combined with irinotecan in order to maximize antitumor activity and potentially minimize postchemotherapeutic deteriorating reaction of cytostatic drug.

Ehrlich ascites tumor; propolis; flavonoids; irinotecan; tumor growth

nije evidentirano